Branded Prescription Drug Fee, Accrual

No definition available.

Name:	exel_BrandedPrescriptionDrugFeeAccrual
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Branded Prescription Drug Fee, Accrual, Current

+ References

No definition available.

+ Details

Name:	exel_BrandedPrescriptionDrugFeeAccrualCurrent
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Branded Prescription Drug Fee, Accrual, Non-Current

+ References

No definition available.

+ Details

Name:	exel_BrandedPrescriptionDrugFeeAccrualNonCurrent
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of Products in Commercial Market

+ References

No definition available.

+ Details

Name:	exel_NumberofProductsinCommercialMarket
Namespace Prefix:	exel_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Organization And Summary Of Significant Policies [Line Items]

+ References

No definition available.

+ Details

Name:	exel_OrganizationAndSummaryOfSignificantPoliciesLineItems
Namespace Prefix:	exel_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

+ Details

Name:	us-gaap_EarningsPerShareBasicAndDiluted
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

+ Details

Name:	us-gaap_GoodwillImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Organization and Summary of Significant Accounting Policies (Details)	3 Months Ended			6 Months Ended
	Jul. 03, 2020 USD ($)	Apr. 03, 2020 USD ($)	Jun. 28, 2019 USD ($)	Jul. 03, 2020 USD ($) segment product $ / shares	Jun. 28, 2019 USD ($)	Jan. 03, 2020 USD ($)
Organization And Summary Of Significant Policies [Line Items]
Number of business segments \| segment				1
Selling, general and administrative	$ 59,791,000		$ 58,815,000	$ 122,731,000	$ 118,953,000
Branded prescription drug fee, accrual	15,100,000			15,100,000		$ 6,000,000.0
Branded prescription drug fee, accrual, current	8,600,000			8,600,000		4,400,000
Branded prescription drug fee, accrual, noncurrent	$ 6,500,000			6,500,000		$ 1,600,000
Goodwill impairment				$ 0
Resulting from discovery efforts
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace \| product				4
Products derived from cabozantinib
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace \| product				2
Products derived from other compounds
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace \| product				2
New information
Organization And Summary Of Significant Policies [Line Items]
Selling, general and administrative		$ 5,400,000
Decrease in earnings per share due to change in accounting estimate (USD per share) \| $ / shares				$ 0.02